Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Bruton’s tyrosine kinase (Btk) is critical for B-cell maturation and activation. Btk loss-of-function mutations cause human X-linked agammaglobulinemia (XLA). In contrast, Btk signaling sustains growth of several B-cell neoplasms which may be treated with tyrosine kinase inhibitors (TKIs). Here, we uncovered the structural mechanism by which certain XLA mutations in the SH2 domain strongly perturb Btk activation. Using a combination of molecular dynamics (MD) simulations and small-angle X-ray scattering (SAXS), we discovered an allosteric interface between the SH2 and kinase domain required for Btk activation and to which multiple XLA mutations map. As allosteric interactions provide unique targeting opportunities, we developed an engineered repebody protein binding to the SH2 domain and able to disrupt the SH2-kinase interaction. The repebody prevents activation of wild-type and TKI-resistant Btk, inhibiting Btk-dependent signaling and proliferation of malignant B-cells. Therefore, the SH2-kinase interface is critical for Btk activation and a targetable site for allosteric inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DAMMIF , a program for rapid ab-initio shape determination in small-angle scattering
Franke, D., & Svergun, D. I. (2009) · Journal of Applied Crystallography · doi:10.1107/s0021889809000338 · Cited by 2,021
Self-citationAccurate assessment of mass, models and resolution by small-angle scattering
Rambo, R. P., & Tainer, J. A. (2013) · Nature · doi:10.1038/nature12070 · Cited by 750
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726 · cited 1×
“Here, allosteric inhibition of Btk in Fc receptor (FcRs) signaling in basophils and mast cells could provide potential therapeutic benefits (Pal Singh et al., 2018).”
BackgroundThe Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citationEide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Panjkovich, A., & Svergun, D. I. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp04540a · Cited by 204
Self-citationFang, Z., Grütter, C., & Rauh, D. (2013) · ACS Chemical Biology · doi:10.1021/cb300663j · Cited by 197
BTKbase: the mutation database for X-linked agammaglobulinemia
Väliaho, J., Smith, C. I. E., & Vihinen, M. (2006) · Human Mutation · doi:10.1002/humu.20410 · Cited by 196
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Quinquenel, A., Fornecker, L.-M., Letestu, R., Ysebaert, L., Fleury, C., Lazarian, G., Dilhuydy, M.-S., Nollet, D., Guieze, R., Feugier, P., et al. (2019) · Blood · doi:10.1182/blood.2019000854 · Cited by 133
Cited by
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Quinquenel, A., Fornecker, L.-M., Letestu, R., Ysebaert, L., Fleury, C., Lazarian, G., Dilhuydy, M.-S., Nollet, D., Guieze, R., Feugier, P., et al. (2019) · Blood · doi:10.1182/blood.2019000854 · Cited by 133
Brookes, E., Rocco, M., Vachette, P., & Trewhella, J. (2023) · Journal of Applied Crystallography · doi:10.1107/s1600576723005344 · Cited by 21
Metadata
- Authors
- Duarte, D. P., Lamontanara, A. J., La Sala, G., Jeong, S., Sohn, Y.-K., Panjkovich, A., Georgeon, S., Kükenshöner, T., Marcaida, M. J., Pojer, F., De Vivo, M., Svergun, D., Kim, H.-S., Dal Peraro, M., & Hantschel, O.
- Venue
- Nature Communications
- Published
- 2020-05-08
- Volume
- 11
- Issue
- 1
- Pages
- 2319-2319
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3022466913
- Cited by
- 44
- References
- 10
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. https://app.cochat.ai/papers/10.1038/s41467-020-16128-5
- The paper
- Duarte, D. P., Lamontanara, A. J., La Sala, G., Jeong, S., Sohn, Y.-K., Panjkovich, A., Georgeon, S., Kükenshöner, T., Marcaida, M. J., Pojer, F., De Vivo, M., Svergun, D., Kim, H.-S., Dal Peraro, M., & Hantschel, O. (2020). Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. Nature Communications. https://doi.org/10.1038/s41467-020-16128-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.